Table 1.

Treatment effects applied in the analysis

	Empagliflozin (SE)	Oral semaglutide (SE)	Source
Change in baseline HbA1c, %	− 0.90 (0.026)	− 1.30 (0.026)	Rodbard et al. 2019 [22]
SBP change from baseline, mmHg	− 4.34 (0.63)	− 4.85 (0.65)	Bain et al. 2020 [20]
DBP change from baseline, mmHg	− 2.67 (0.44)	− 2.27 (0.45)	Bain et al. 2020 [20]
Total cholesterol change from baseline, mg/dl	4.74 (1.57)	− 5.08 (1.62)	Bain et al. 2020 [20]
HDL cholesterol change from baseline, mg/dl	3.11 (0.34)	0.73 (0.35)	Bain et al. 2020 [20]
BMI change from baseline, kg/m2	− 1.294 (0.028)	− 1.357 (0.028)	Rodbard et al. 2019 [22]

For the base case analysis, results based on the treatment estimand of the PIONEER 2 study were used

BMI body mass index, DBP diastolic blood pressure, HbA1c haemoglobin A1c, HDL high-density lipoprotein, SBP systolic blood pressure, SE standard error